Fig. 3

Single and consecutive administration of TMP significantly suppressed CCI-induced activation of MMP-2/9 in vivo. a Single administration of TMP (30 mg/kg, i.p.) significantly suppressed CCI-induced activation of MMP-2 and MMP-9 in the spinal cords. b Consecutive administration of TMP (30 mg/kg, i.p.) for 5 days from 14 days after the CCI operation significantly attenuated CCI-induced activation of MMP-2 and MMP-9 in the spinal cord. The gelatin zymography samples (n = 6) were collected as described above. c Single administration of TMP (30 mg/kg, i.p.) significantly attenuated CCI-induced increase in the expression of MMP-2 and MMP-9. d Consecutive administration of TMP (30 mg/kg, i.p.) significantly attenuated CCI-induced increase in the expression of MMP-2 and MMP-9. The levels of MMP-2 and MMP-9 mRNA in the spinal cord were determined using real-time quantitative PCR. GAPDH was used as an invariant control. e Single administration of TMP (30 mg/kg, i.p.) significantly attenuated CCI-induced increase in the expression of MMP-2 and MMP-9. f Consecutive administration of TMP (30 mg/kg, i.p.) significantly attenuated CCI-induced increase in the expression of MMP-2 and MMP-9. The lumbar spines (L1–L6) were collected and analyzed using western blot. A significant difference was at *P < 0.05, **P < 0.01 vs. control; ^# P < 0.05, ^## P < 0.01 vs. CCI group